This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 2042466 results found since Jan 2013.
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Conditions: Advanced Solid Tumor; Refractory Tumor Interventions: Radiation: Radiotherapy; Drug: PD-1/PD-L1 inhibitor; Drug: Granulocyte-macrophage colony-stimulating factor subcutaneous injection; Drug: Interleukin 2 subcutaneous injection; Drug: Endostatin Sponsor: Second Affiliated Hospital of Soochow University Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions: NAFLD; MASLD; Mild Inflammatory Context Intervention: Dietary Supplement: TOTUM-448 Sponsors: Valbiotis; Clinic'n'Cell; University Hospital, Clermont-Ferrand Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: Autologous Natural Killer Cell Therapy; Device: Clinimacs Plus Sponsor: Dr Cipto Mangunkusumo General Hospital Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma Intervention: Biological: RC19D2 cell injection Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Condition: Large B-Cell Lymphoma Interventions: Drug: Glofitamab; Drug: Polatuzumab vedotin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone Sponsor: Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Needs and Preferences of Patients With Head-neck Cutaneous SCC
Conditions: Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Squamous Cell Carcinoma of the Head and Neck; Skin Cancer; Patient Satisfaction; High-Risk Cance r; Preference, Patient; Decision Making; Interview Intervention: Other: Regular care with additional administration of a semi-structured interview Sponsor: Maastricht University Medical Center Active, not recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer Intervention: Drug: PLB1004 Sponsor: Avistone Biotechnology Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Conditions: Head Neck; Squamous Cell Carcinoma of Head and Neck Interventions: Drug: Pembrolizumab; Drug: Magrolimab; Drug: cetuximab; Drug: Docetaxel Sponsors: M.D. Anderson Cancer Center; Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Conditions: Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, B-Cell Intervention: Drug: ALETA-001 Sponsors: Cancer Research UK; Aleta BioTherapeutics Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Condition: Multiple Myeloma Interventions: Biological: idecabtagene vicleucel; Drug: Lenalidomide; Drug: Fludarabine; Drug: Cyclophosphamide Sponsor: Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer
Condition: Non-small Cell Lung Cancer Metastatic Intervention: Sponsors: Ari Raphael; Bar-Ilan University, Israel; Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation
Conditions: Cystic Fibrosis; Congenital Bilateral Absence of Vas Deferens; Sterility, Male Intervention: Procedure: Epididymal sample Sponsor: University Hospital, Brest Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Condition: Relapsed or Refractory B-cell Lymphoma Intervention: Biological: infusion of JY231 injection Sponsor: Guangdong Second Provincial General Hospital Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Borrelia B-cell Diagnostics
Conditions: Lyme Disease; Borrelia Infections Intervention: Procedure: venous blood puncture Sponsors: University Children's Hospital, Zurich; Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Condition: Large B-cell Lymphoma Interventions: Drug: Prednisone; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Epcoritamab Sponsor: M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
